Första AP-fonden’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $8.61M | Buy |
26,400
+600
| +2% | +$196K | 0.06% | 288 |
|
|
2025
Q1 | $6.97M | Sell |
25,800
-29,000
| -53% | -$7.83M | 0.05% | 312 |
|
|
2024
Q4 | $12.9M | Buy |
54,800
+3,900
| +8% | +$918K | 0.09% | 204 |
|
|
2024
Q3 | $14M | Buy |
50,900
+25,700
| +102% | +$7.07M | 0.11% | 184 |
|
|
2024
Q2 | $6.12M | Sell |
25,200
-43,100
| -63% | -$10.5M | 0.05% | 313 |
|
|
2024
Q1 | $10.2M | Buy |
68,300
+45,500
| +200% | +$6.8M | 0.09% | 235 |
|
|
2023
Q4 | $4.36M | Sell |
22,800
-2,600
| -10% | -$498K | 0.04% | 382 |
|
|
2023
Q3 | $4.5M | Buy |
25,400
+500
| +2% | +$88.6K | 0.05% | 368 |
|
|
2023
Q2 | $4.73M | Sell |
24,900
-900
| -3% | -$171K | 0.05% | 375 |
|
|
2023
Q1 | $5.17M | Sell |
25,800
-2,800
| -10% | -$561K | 0.06% | 337 |
|
|
2022
Q4 | $6.8M | Buy |
28,600
+5,500
| +24% | +$1.31M | 0.08% | 311 |
|
|
2022
Q3 | $4.62M | Sell |
23,100
-5,900
| -20% | -$1.18M | 0.06% | 361 |
|
|
2022
Q2 | $4.23M | Buy |
29,000
+5,700
| +24% | +$831K | 0.06% | 375 |
|
|
2022
Q1 | $3.81M | Sell |
23,300
-500
| -2% | -$81.7K | 0.04% | 433 |
|
|
2021
Q4 | $4.04M | Buy |
23,800
+500
| +2% | +$84.8K | 0.04% | 434 |
|
|
2021
Q3 | $4.4M | Buy |
23,300
+9,900
| +74% | +$1.87M | 0.05% | 420 |
|
|
2021
Q2 | $2.27M | Sell |
13,400
-11,600
| -46% | -$1.97M | 0.03% | 485 |
|
|
2021
Q1 | $3.53M | Buy |
25,000
+1,600
| +7% | +$226K | 0.05% | 436 |
|
|
2020
Q4 | $3.04M | Buy |
23,400
+4,800
| +26% | +$624K | 0.05% | 424 |
|
|
2020
Q3 | $2.71M | Buy |
18,600
+4,100
| +28% | +$597K | 0.06% | 373 |
|
|
2020
Q2 | $2.15M | Sell |
14,500
-1,700
| -10% | -$252K | 0.06% | 352 |
|
|
2020
Q1 | $1.76M | Buy |
+16,200
| New | +$1.76M | 0.06% | 355 |
|